Medtronic (the manufacturer of the Captiva Thoracic Stent Graft System) is collecting information about the Captiva Thoracic Stent Graft System in this post approval study. The purpose of the study is to evaluate the long-term performance of the Captiva Thoracic Stent Graft System to gain additional information regarding the safety and effectiveness of it. This graft has been approved by the US Food and Drug Administration (FDA) for the treatment of descending thoracic aortic aneurysms.
Male and non-pregnant female patients who are 18 years or older and have been diagnosed with a descending thoracic aortic aneurysm are eligible.
Patients will undergo a physical examination and a CT or MRA of their aneurysms. After hospital discharge, they will return to the clinic for 1 month, 6 month, and annual visits for five years at which they will undergo a physical examination, CT or MRA of the chest, and X-ray of the chest.
Patients will be in the study for approximately five years.
Please contact Tiffany Whitaker, R.N., at (217) 545-2531 or email:email@example.com
Kim Hodgson, MD